Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Marks Group Wealth Management Inc

Marks Group Wealth Management Inc lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 0.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 20,502 shares of the company’s stock after purchasing an additional 106 shares during the quarter. Marks Group Wealth Management Inc’s holdings in Novo Nordisk A/S were worth $2,121,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of NVO. Westside Investment Management Inc. raised its position in Novo Nordisk A/S by 83.3% in the 3rd quarter. Westside Investment Management Inc. now owns 1,428 shares of the company’s stock valued at $130,000 after purchasing an additional 649 shares in the last quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD purchased a new stake in shares of Novo Nordisk A/S in the third quarter valued at approximately $2,408,000. Lazard Asset Management LLC boosted its stake in shares of Novo Nordisk A/S by 182.2% in the third quarter. Lazard Asset Management LLC now owns 1,494,214 shares of the company’s stock valued at $135,883,000 after buying an additional 964,640 shares in the last quarter. Benedict Financial Advisors Inc. boosted its stake in shares of Novo Nordisk A/S by 94.0% in the third quarter. Benedict Financial Advisors Inc. now owns 44,292 shares of the company’s stock valued at $4,028,000 after buying an additional 21,457 shares in the last quarter. Finally, CENTRAL TRUST Co boosted its stake in shares of Novo Nordisk A/S by 111.6% in the third quarter. CENTRAL TRUST Co now owns 6,004 shares of the company’s stock valued at $546,000 after buying an additional 3,166 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on NVO. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target for the company. BMO Capital Markets began coverage on Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 target price on the stock. Finally, UBS Group started coverage on Novo Nordisk A/S in a report on Tuesday, January 16th. They set a “neutral” rating on the stock. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Price Performance

Shares of NVO traded up $2.97 during midday trading on Tuesday, reaching $128.23. The stock had a trading volume of 2,402,406 shares, compared to its average volume of 4,838,394. Novo Nordisk A/S has a 52 week low of $75.56 and a 52 week high of $138.28. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. The firm’s 50 day moving average price is $126.49 and its 200-day moving average price is $111.28. The company has a market capitalization of $575.44 billion, a P/E ratio of 47.34, a P/E/G ratio of 2.05 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The company had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. On average, analysts forecast that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were given a dividend of $0.664 per share. The ex-dividend date was Friday, March 22nd. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a dividend yield of 0.9%. Novo Nordisk A/S’s payout ratio is 49.17%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.